Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11529)
All Articles published online
|
Publishing Process of This Article
|
May 7, 2015 (publication date) through Jun 5, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World J Gastroenterol 2015; 21(17): 5352-5358 [PMID: 25954110 DOI: 10.3748/wjg.v21.i17.5352] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i17/5352.htm |
| Number | Citing Articles |
| 1 |
Yukiya Narita, Kei Muro. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. Expert Opinion on Drug Safety 2017; 16(3): 319 doi: 10.1080/14740338.2017.1273348
|
| 2 |
Siavash Foroughi, Hui‐li Wong, Lucy Gately, Margaret Lee, Koen Simons, Jeanne Tie, Antony Wilks Burgess, Peter Gibbs. Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial. Asia-Pacific Journal of Clinical Oncology 2018; 14(6): 365 doi: 10.1111/ajco.12992
|
| 3 |
Jane McKenzie, Vanessa Wong, Shehara Mendis, Rachel Wong, Suzanne Kosmider, Yat Hang To, Louise Nott, Jeremy Shapiro, Javier Torres, Belinda Lee, Azim Jalali, Stephanie Hui-Su Lim, Susan Caird, Adnan Khattak, Peter Gibbs. Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2025; doi: 10.1016/j.clcc.2025.04.001
|
| 4 |
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531
|
| 5 |
S.I. Panin, V.A. Suvorov, N.V. Kovalenko, A.V. Bykov, M.P. Postolov, A.M. Linchenko, O.A. Kosivtsov, E.S. Mikhin. Perforated peptic ulcer in patients with cancer: prediction of postoperative morbidity and mortality. Khirurgiya. Zhurnal im. N.I. Pirogova 2022; (7): 12 doi: 10.17116/hirurgia202207112
|